Organogenesis Holdings Inc. provided earnings guidance for the Fiscal Year 2023. For the year, the company expects Net revenue between $454 million and $466 million, representing an increase of approximately 1% to 3% year-over-year, as compared to net revenue of $450.9 million for the year ended December 31, 2022. Net income between $3 million and $11 million and adjusted net income between $8 million and $16 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.66 USD | -3.27% | +2.31% | -34.96% |
May. 13 | Morgan Stanley Lowers Price Target on Organogenesis Holdings to $3 From $3.50, Keeps Equalweight Rating | MT |
May. 10 | Health Care Edges Higher Amid Rotation to Utilities - Health Care Roundup | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-34.96% | 365M | |
+49.41% | 57.87B | |
+41.65% | 40.25B | |
-6.72% | 39.94B | |
-5.96% | 28.54B | |
+12.99% | 26.4B | |
-19.82% | 19.33B | |
+32.35% | 12.4B | |
-0.08% | 12.23B | |
+25.18% | 12.2B |
- Stock Market
- Equities
- ORGO Stock
- News Organogenesis Holdings Inc.
- Organogenesis Holdings Inc. Provides Earnings Guidance for the Fiscal Year 2023